- Home
- SISI vs LYRA Comparison
SISI vs LYRA Comparison
Compare SISI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- LYRA
- Stock Information
- Founded
- SISI 1997
- LYRA 2005
- Country
- SISI China
- LYRA United States
- Employees
- SISI N/A
- LYRA N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- LYRA Medical/Dental Instruments
- Sector
- SISI Health Care
- LYRA Health Care
- Exchange
- SISI Nasdaq
- LYRA Nasdaq
- Market Cap
- SISI 14.9M
- LYRA 15.0M
- IPO Year
- SISI 2016
- LYRA 2020
- Fundamental
- Price
- SISI $0.21
- LYRA $9.40
- Analyst Decision
- SISI
- LYRA Buy
- Analyst Count
- SISI 0
- LYRA 2
- Target Price
- SISI N/A
- LYRA $16.00
- AVG Volume (30 Days)
- SISI 5.5M
- LYRA 1.9M
- Earning Date
- SISI 05-15-2025
- LYRA 08-13-2025
- Dividend Yield
- SISI N/A
- LYRA N/A
- EPS Growth
- SISI N/A
- LYRA N/A
- EPS
- SISI N/A
- LYRA N/A
- Revenue
- SISI $9,601,324.00
- LYRA $1,185,000.00
- Revenue This Year
- SISI N/A
- LYRA N/A
- Revenue Next Year
- SISI N/A
- LYRA $1,286.17
- P/E Ratio
- SISI N/A
- LYRA N/A
- Revenue Growth
- SISI 1133.26
- LYRA N/A
- 52 Week Low
- SISI $0.18
- LYRA $3.81
- 52 Week High
- SISI $117.65
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- SISI 29.00
- LYRA 45.31
- Support Level
- SISI $0.18
- LYRA $10.15
- Resistance Level
- SISI $0.34
- LYRA $14.88
- Average True Range (ATR)
- SISI 0.05
- LYRA 2.03
- MACD
- SISI -0.01
- LYRA -0.67
- Stochastic Oscillator
- SISI 11.25
- LYRA 0.42
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.